Medicines containing active substance Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)
This site has the patient leaflet or the SPC of 1 medicine with the active substance allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2).
- 1 allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2) only
Medicines containing only allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)
| Medicine | Legal category |
|---|---|
| Zalmoxis SPC | – |
ATC groups
The ATC classification sorts medicines by the organ they act on and by their effect – the group pages list the other medicines of the group too.
- L01 Antineoplastic agents 1 medicine
Sources: the MHRA product information and the European Medicines Agency (patient leaflets and SPCs), the NHS Dictionary of Medicines and Devices (dm+d), NHS Business Services Authority (substances, ATC codes and legal categories). Contains public sector information licensed under the Open Government Licence v3.0. Ask your doctor or pharmacist which medicine is right for you.